Clinical Trials Browser

Completed × auricularum × 1 year × Clear all

NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03367572 2025-09-25

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Phase 3 Completed

1,363 enrolled 20 charts

Breast

Breast Neoplasms

NCT01415882 2025-09-05

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Phase 2 Completed

165 enrolled 15 charts

Plasma cell

Multiple Myeloma

NCT02819024 2025-08-22

Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

Phase NA Completed

6 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2/3 Completed

130 enrolled 8 charts

Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Phase 1/2 Completed

87 enrolled 13 charts

Plasma cell

Amyloidosis, Multiple Myeloma

NCT03713294 2025-06-24

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Phase 2 Completed

37 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT03012880 2025-06-04

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

80 enrolled 12 charts

Plasma cell

Multiple Myeloma